Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Pharmacokinetics and Sedative Effects of Intranasal Dexmedetomidine in Ambulatory Pediatric Patients.

Uusalo P, Guillaume S, Siren S, Manner T, Vilo S, Scheinin M, Saari TI.

Anesth Analg. 2019 Jun 12. doi: 10.1213/ANE.0000000000004264. [Epub ahead of print]

PMID:
31206433
2.

Premedication with intranasal dexmedetomidine decreases barbiturate requirement in pediatric patients sedated for magnetic resonance imaging: a retrospective study.

Uusalo P, Lehtinen M, Löyttyniemi E, Manner T, Scheinin M, Saari TI.

BMC Anesthesiol. 2019 Feb 13;19(1):22. doi: 10.1186/s12871-019-0690-1.

3.

Intranasal Low-Dose Dexmedetomidine Reduces Postoperative Opioid Requirement in Patients Undergoing Hip Arthroplasty Under General Anesthesia.

Uusalo P, Jätinvuori H, Löyttyniemi E, Kosola J, Saari TI.

J Arthroplasty. 2019 Apr;34(4):686-692.e2. doi: 10.1016/j.arth.2018.12.036. Epub 2019 Jan 7.

PMID:
30733071
4.
5.

Voriconazole greatly increases the exposure to oral buprenorphine.

Fihlman M, Hemmilä T, Hagelberg NM, Backman JT, Laitila J, Laine K, Neuvonen PJ, Olkkola KT, Saari TI.

Eur J Clin Pharmacol. 2018 Dec;74(12):1615-1622. doi: 10.1007/s00228-018-2548-8. Epub 2018 Aug 30.

PMID:
30167757
6.

Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug Interaction Between S-ketamine and Ticlopidine in Healthy Human Volunteers.

Ashraf MW, Peltoniemi MA, Olkkola KT, Neuvonen PJ, Saari TI.

CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):687-697. doi: 10.1002/psp4.12346. Epub 2018 Sep 10.

7.

Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers.

Uusalo P, Al-Ramahi D, Tilli I, Aantaa RA, Scheinin M, Saari TI.

Eur J Clin Pharmacol. 2018 Aug;74(8):1047-1054. doi: 10.1007/s00228-018-2461-1. Epub 2018 Apr 17.

PMID:
29666901
8.

Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.

Hagelberg NM, Fihlman M, Hemmilä T, Backman JT, Laitila J, Neuvonen PJ, Laine K, Olkkola KT, Saari TI.

Pharmacol Res Perspect. 2016 Nov 3;4(6):e00271. doi: 10.1002/prp2.271. eCollection 2016 Dec.

9.

Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.

Fihlman M, Hemmilä T, Hagelberg NM, Kuusniemi K, Backman JT, Laitila J, Laine K, Neuvonen PJ, Olkkola KT, Saari TI.

Eur J Clin Pharmacol. 2016 Nov;72(11):1363-1371. Epub 2016 Aug 10.

PMID:
27510521
10.

Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.

Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI.

Clin Pharmacokinet. 2016 Sep;55(9):1059-77. doi: 10.1007/s40262-016-0383-6. Review.

PMID:
27028535
11.

Patient-controlled Analgesia with Target-controlled Infusion of Hydromorphone in Postoperative Pain Therapy.

Jeleazcov C, Ihmsen H, Saari TI, Rohde D, Mell J, Fröhlich K, Krajinovic L, Fechner J, Schwilden H, Schüttler J.

Anesthesiology. 2016 Jan;124(1):56-68. doi: 10.1097/ALN.0000000000000937.

PMID:
26556729
12.

Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.

Saarikoski T, Saari TI, Hagelberg NM, Backman JT, Neuvonen PJ, Scheinin M, Olkkola KT, Laine K.

Eur J Clin Pharmacol. 2015 Mar;71(3):321-7. doi: 10.1007/s00228-014-1799-2. Epub 2015 Jan 6.

PMID:
25560051
13.

Influence of intensive care treatment on the protein binding of sufentanil and hydromorphone during pain therapy in postoperative cardiac surgery patients.

Saari TI, Ihmsen H, Mell J, Fröhlich K, Fechner J, Schüttler J, Jeleazcov C.

Br J Anaesth. 2014 Oct;113(4):677-87. doi: 10.1093/bja/aeu160. Epub 2014 Jul 6.

14.

Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy.

Jeleazcov C, Saari TI, Ihmsen H, Mell J, Fröhlich K, Krajinovic L, Fechner J, Schüttler J.

Anesthesiology. 2014 Feb;120(2):378-91. doi: 10.1097/ALN.0b013e3182a76d05.

PMID:
23958818
15.

A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Frechen S, Junge L, Saari TI, Suleiman AA, Rokitta D, Neuvonen PJ, Olkkola KT, Fuhr U.

Clin Pharmacokinet. 2013 Sep;52(9):763-81. doi: 10.1007/s40262-013-0070-9.

PMID:
23653047
16.

Does the pharmacology of oxycodone justify its increasing use as an analgesic?

Olkkola KT, Kontinen VK, Saari TI, Kalso EA.

Trends Pharmacol Sci. 2013 Apr;34(4):206-14. doi: 10.1016/j.tips.2013.02.001. Epub 2013 Mar 4. Review.

PMID:
23465410
17.

Rifampicin markedly decreases the exposure to oral and intravenous tramadol.

Saarikoski T, Saari TI, Hagelberg NM, Neuvonen M, Neuvonen PJ, Scheinin M, Olkkola KT, Laine K.

Eur J Clin Pharmacol. 2013 Jun;69(6):1293-301. doi: 10.1007/s00228-012-1460-x. Epub 2012 Dec 15.

PMID:
23242004
18.

[Dexmedetomidine. Pharmacokinetics and pharmacodynamics].

Ihmsen H, Saari TI.

Anaesthesist. 2012 Dec;61(12):1059-66. doi: 10.1007/s00101-012-2114-1. Review. German.

PMID:
23223843
19.

Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction.

Hagelberg NM, Saarikoski T, Saari TI, Neuvonen M, Neuvonen PJ, Turpeinen M, Scheinin M, Laine K, Olkkola KT.

Eur J Clin Pharmacol. 2013 Apr;69(4):867-75. doi: 10.1007/s00228-012-1433-0. Epub 2012 Oct 26.

PMID:
23099620
20.

Analysis of total and unbound hydromorphone in human plasma by ultrafiltration and LC-MS/MS: application to clinical trial in patients undergoing open heart surgery.

Saari TI, Fechner J, Ihmsen H, Schüttler J, Jeleazcov C.

J Pharm Biomed Anal. 2012 Dec;71:63-70. doi: 10.1016/j.jpba.2012.07.025. Epub 2012 Jul 31.

PMID:
22884788
21.

Changes in total and unbound concentrations of sufentanil during target controlled infusion for cardiac surgery with cardiopulmonary bypass.

Jeleazcov C, Saari TI, Ihmsen H, Schüttler J, Fechner J.

Br J Anaesth. 2012 Nov;109(5):698-706. doi: 10.1093/bja/aes253. Epub 2012 Jul 24.

22.

Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine.

Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Kurkinen KJ, Neuvonen PJ, Olkkola KT.

Basic Clin Pharmacol Toxicol. 2012 Nov;111(5):325-32. doi: 10.1111/j.1742-7843.2012.00908.x. Epub 2012 Jun 27.

23.

Determination of total and unbound sufentanil in human plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetic study.

Saari TI, Fechner J, Ihmsen H, Schüttler J, Jeleazcov C.

J Pharm Biomed Anal. 2012 Jul;66:306-13. doi: 10.1016/j.jpba.2012.03.050. Epub 2012 Apr 3.

PMID:
22522038
24.

S-ketamine concentrations are greatly increased by grapefruit juice.

Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT.

Eur J Clin Pharmacol. 2012 Jun;68(6):979-86. doi: 10.1007/s00228-012-1214-9.

PMID:
22286159
25.

Re: Pergolizzi et al. 2011: Exposure to potential CYP450 pharmacokinetic drug-drug interactions.

Nieminen TH, Hagelberg NM, Saari TI, Grönlund J, Neuvonen PJ, Olkkola KT.

Pain Pract. 2012 Jan;12(1):81-2. doi: 10.1111/j.1533-2500.2011.00506.x. No abstract available.

PMID:
22230379
26.

Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study.

Saari TI, Ihmsen H, Neuvonen PJ, Olkkola KT, Schwilden H.

Br J Anaesth. 2012 Mar;108(3):491-8. doi: 10.1093/bja/aer395. Epub 2011 Dec 26.

27.

Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.

Peltoniemi MA, Saari TI, Hagelberg NM, Reponen P, Turpeinen M, Laine K, Neuvonen PJ, Olkkola KT.

Clin Pharmacol Ther. 2011 Aug;90(2):296-302. doi: 10.1038/clpt.2011.140. Epub 2011 Jun 29.

PMID:
21716267
28.

St John's wort greatly decreases the plasma concentrations of oral S-ketamine.

Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT.

Fundam Clin Pharmacol. 2012 Dec;26(6):743-50. doi: 10.1111/j.1472-8206.2011.00954.x. Epub 2011 Jun 2.

PMID:
21635359
29.

Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology.

Saari TI, Uusi-Oukari M, Ahonen J, Olkkola KT.

Pharmacol Rev. 2011 Mar;63(1):243-67. doi: 10.1124/pr.110.002717. Epub 2011 Jan 18. Review.

PMID:
21245208
30.

Interaction of oxycodone and voriconazole-a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects.

Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT.

Eur J Clin Pharmacol. 2011 Aug;67(8):863-4. doi: 10.1007/s00228-010-0969-0. Epub 2011 Jan 11. No abstract available.

PMID:
21221959
31.

Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4.

Grönlund J, Saari TI, Hagelberg N, Neuvonen PJ, Olkkola KT, Laine K.

Antimicrob Agents Chemother. 2011 Mar;55(3):1063-7. doi: 10.1128/AAC.01242-10. Epub 2010 Dec 20.

32.

Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study.

Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Laine K, Olkkola KT.

Clin Drug Investig. 2011;31(3):143-53. doi: 10.2165/11539950-000000000-00000.

PMID:
21142269
33.

Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir.

Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT.

Eur J Clin Pharmacol. 2010 Oct;66(10):977-85. doi: 10.1007/s00228-010-0879-1. Epub 2010 Aug 10.

PMID:
20697700
34.

Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K.

Br J Clin Pharmacol. 2010 Jul;70(1):78-87. doi: 10.1111/j.1365-2125.2010.03653.x.

35.

Azole antimycotics and drug interactions in the perioperative period.

Saari TI, Olkkola KT.

Curr Opin Anaesthesiol. 2010 Aug;23(4):441-8. doi: 10.1097/ACO.0b013e32833a254d. Review.

PMID:
20610983
36.

Grapefruit juice enhances the exposure to oral oxycodone.

Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT.

Basic Clin Pharmacol Toxicol. 2010 Oct;107(4):782-8. doi: 10.1111/j.1742-7843.2010.00582.x.

37.

St John's wort greatly reduces the concentrations of oral oxycodone.

Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT.

Eur J Pain. 2010 Sep;14(8):854-9. doi: 10.1016/j.ejpain.2009.12.007. Epub 2010 Jan 27.

PMID:
20106684
38.

Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.

Saari TI, Grönlund J, Hagelberg NM, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT.

Eur J Clin Pharmacol. 2010 Apr;66(4):387-97. doi: 10.1007/s00228-009-0775-8.

PMID:
20076952
39.

Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine.

Hagelberg NM, Peltoniemi MA, Saari TI, Kurkinen KJ, Laine K, Neuvonen PJ, Olkkola KT.

Eur J Pain. 2010 Jul;14(6):625-9. doi: 10.1016/j.ejpain.2009.10.003. Epub 2009 Nov 7.

PMID:
19897389
40.

Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.

Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT.

Anesthesiology. 2009 Jun;110(6):1371-8. doi: 10.1097/ALN.0b013e31819faa54.

PMID:
19417618
41.

Voriconazole drastically increases exposure to oral oxycodone.

Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT.

Eur J Clin Pharmacol. 2009 Mar;65(3):263-71. doi: 10.1007/s00228-008-0568-5. Epub 2008 Oct 3.

PMID:
18836708
42.

Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl.

Saari TI, Laine K, Neuvonen M, Neuvonen PJ, Olkkola KT.

Eur J Clin Pharmacol. 2008 Jan;64(1):25-30. Epub 2007 Nov 7.

PMID:
17987285
43.

Voriconazole and fluconazole increase the exposure to oral diazepam.

Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT.

Eur J Clin Pharmacol. 2007 Oct;63(10):941-9. Epub 2007 Aug 4.

PMID:
17676319
44.

Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.

Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT.

Clin Pharmacol Ther. 2006 Nov;80(5):502-8.

PMID:
17112806
45.

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects.

Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT.

Br J Clin Pharmacol. 2007 Jan;63(1):116-20. Epub 2006 Jul 6.

46.

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.

Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT.

Clin Pharmacol Ther. 2006 Apr;79(4):362-70.

PMID:
16580904

Supplemental Content

Loading ...
Support Center